A Global Leading Company in Antibody Therapeutics 항체신약발굴 전문회사 와이바이오로직스

Platform technologies and pipelines 파이프라인

파이프라인
Pipeline
(Target)
Disease Drug
Format
Candidate Selection for Development

Development

Chance for
collaboration

Target
discovery
Ab
screening
Ab
characterization
Efficacy
test

CMC /
non-clinical study

AR-001
(YBL-001)
Cancer ADC
Combi-, non-ADC
approach
AR-003
(YBL-002)
Cancer Naked
Ab

No restriction

YBL-003 Cancer Immune
modulating Ab

Some restriction
(need to confirm)

YBL-004 Autoimmune
diseases
Bispecific
Ab

No restriction

YBL-005

Multiple
Sclerosis

biobetter

No restriction

YBL-006 Cancer Immune
modulating Ab

Some restriction
(need to confirm)

YBL-007 Cancer Immune
modulating Ab

Some restriction
(need to confirm)